Todas las noticias

The Board of Directors of Spineway, meeting on September 18, 2023, under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, 2023.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its Spineway Academy department, with the support of GECO1(Groupe d’études de la Chirurgie Osseuse – Bone Surgery Study Group) and its SAC (Spine Arthroplasty Community) working group, has organized a masterclass on cervical and lumbar disc prostheses with French and international surgeons. This event was held on September 9 in Behoust (France) and focused on total disc replacement using prostheses.

Spineway’s total revenue for the first half of 2023 was €5.4 million, up 75% compared with the first half of 2022. Growth was driven mainly by the contribution of sales of Spine Innovations, acquired in July 2022. However, organic growth1 remained sustained, representing 12% in the first half of 2023, thanks to the steep increase in Distimp sales (+66%), demonstrating the momentum spurred by the Group’s commercial activity over the period.

Spineway, a specialist in innovative implants for the treatment of severe disorders of the spinal column, has been on a new growth trajectory for more than a year, driven by the acquisitions of Distimp in June 2021 and Spine Innovations in July 2022. These acquisitions have enabled it to extend its geographical footprint, to offer two operating techniques – fusion and non-fusion – and to stimulate product innovation

Spineway has achieved a total revenue of €2.4 million as of Q1 2023, representing growth of 79% compared with Q1 2022, mainly driven by sales of Spine Innovations’ disc prostheses. Adjusted for this contribution, quarterly revenue remainsrobust and represents an all-time high of €1.4 million despite a temporary delay in Latin America due to regulatory procedures for the approval of new products.

The Ordinary and Extraordinary General Meeting of Spineway's shareholders was held on first call on Tuesday, April 4, 2023 at 11:00 a.m. at the Group's registered office, 7 allée Moulin Berger in Ecully (69)

Spineway informs its shareholders that they are invited to attend the Combined General Meeting to be held on Tuesday, April 4, 2023 at 11:00 a.m. at the Group's headquarters, 7 allée Moulin Berger in Ecully (69).

2022 illustrates the strong momentum generated by management, combining targeted external growth, international business development and the acceleration of an ambitious R&D program aimed at making the Group a reference player in spine surgery with Premium positioning.

SPINEWAY (ISIN : FR0011398874 – ALSPW), a specialist in innovative implants for the treatment of severe spine pathologies, announced today its 2023 financial calendar.